Alterity Therapeutics Limited

ASX:ATH.AX

0 (AUD) • At close September 6, 2024
Bedrijfsnaam Alterity Therapeutics Limited
Symbool ATH.AX
Munteenheid AUD
Prijs 0.003
Beurswaarde 18,621,176
Dividendpercentage 0%
52-weken bereik 0.003 - 0.009
Industrie Biotechnology
Sector Healthcare
CEO Mr. Geoffrey Paul Kempler B.Sc, B.Sc.
Website https://alteritytherapeutics.com

An error occurred while fetching data.

Over Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing

Vergelijkbare Aandelen

IDT Australia Limited logo

IDT Australia Limited

IDT.AX

0.115 AUD

Neurotech International Limited logo

Neurotech International Limited

NTI.AX

0.068 AUD

Althea Group Holdings Limited logo

Althea Group Holdings Limited

AGH.AX

0.02 AUD

Resonance Health Limited logo

Resonance Health Limited

RHT.AX

0.062 AUD

Lumos Diagnostics Holdings Limited logo

Lumos Diagnostics Holdings Limited

LDX.AX

0.042 AUD

Cryosite Limited logo

Cryosite Limited

CTE.AX

0.75 AUD

Imricor Medical Systems, Inc. logo

Imricor Medical Systems, Inc.

IMR.AX

0.505 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)